Skip to main content
. 2022 Aug 31;50:60. doi: 10.1186/s41182-022-00456-x

Table 3.

Subgroup analysis of results by number of drugs and status of patients with COVID-19 after treatment

Subgroup N Sample size Heterogeneity (I2) Egger test Prevalence (95% CI)
Polypharmacy by drug number 4–9 5 35,788 98.5 0.631 26.8 (95% CI: 18.5–37.1)
 > 10 6 99,416 99.8 0.751 17.1 (95% CI: 11.6–24.3)
Patient status after treatment Survivors 9 5490 98.2 0.144 42.1 (95% CI: 28.9–56.6)
Non-survivors 9 1508 88.3 0.972 54.8 (95% CI: 45.4–63.9)